Search results for: Consulting Reports
Filter search results
Value and Cancer: Journal of Cancer Policy Special Issue
25 January 2017
…P., Garau, M., Welin, K-O., Bianchi, S., Althin, R., O’Neill, P., Persson, U., and Towse, A., 2016. Improving Efficiency and Resource Allocation in Future Cancer Care. Consulting Report. London: Office of…
What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?
9 July 2018
…The term indication-based pricing (IBP) is often used in medical and health economics literature to refer to this concept. In an OHE Consulting report published last month, Towse, Cole and…
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
…product will reach the market at all. Towse, A. and Garau, M. (2018). Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence. OHE Consulting Report. RePEc Zamora, B.,…
OHE at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare October, 2018
5 November 2018
…presented on Indication Based Pricing: A better way to value drugs? setting out the arguments for and against differential pricing by indication. This built on work from an OHE consulting…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
…and Cures: A Discrete Choice Experiment. OHE Consulting Report, London: Office of Health Economics. RePEc. Marsden, G. and Towse, A., 2017. Exploring the Assessment and Appraisal of Regenerative Medicines and Cell…
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
22 March 2019
…and Garau, M., 2018. Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence. OHE Consulting Report. RePEc. Pearson S., 2019. Early Experience with Health Technology Assessment of Gene Therapies…
NICE’s severity modifier: a step in the right direction, but still a long way to go
23 March 2022
…literature. Social Science & Medicine, 204, 39–50. Zhang, K., and Garau, M. 2020. International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making. OHE Consulting Report. Zhang, K., Kumar, G., &…
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
…– is critical. Citation Cookson, G. and Hitch, J. (2021) Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers. OHE Consulting Report. Available at: https://www.ohe.org/publications/limitations-cbo%E2%80%99s-simulation….
Exploring the Interdependency between Public and Charitable Medical Research
1 April 2011
Continuing concern about the fiscal deficit makes it likely that government funding of health and medical research will remain under scrutiny. This OHE Consulting study, commissioned by Cancer Research UK,…